This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kulke, M. H. Articles by Fuchs, C. S. Search for Related Content PubMed Articles by Kulke, M. H. Articles by Fuchs, C. S. Related Articles Related Correspondence Social Bookmarking                            What's this?

In Reply

Dana-Farber Cancer Institute, Gastrointestinal Cancer Center, Boston, MA

We appreciate the comments of Drs Boeck and Heinemann regarding our study of capecitabine and erlotinib in patients with gemcitabine-refractory advanced pancreatic cancer.¹ We concur that the role of second-line treatment has been understudied in this disease. The results of our study, taken together with the data from the other studies they describe, suggest that the administration of second-line therapy has the potential to positively influence overall survival. Larger studies formally investigating the role of second-line therapy in advanced pancreatic cancer are warranted.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None Consultant or Advisory Role: Matthew H. Kulke, Novartis (C); Charles S. Fuchs, Roche (C), sanofi-aventis (C), Pfizer (C), AstraZeneca (C), Bristol-Meyers Squibb (C), Amgen (C), Genentech (C) Stock Ownership: None Honoraria: None Research Funding: None Expert Testimony: None Other Remuneration: None

REFERENCE

1. Kulke MH, Blaszkowsky LS, Ryan DR, et al: Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787-4792, 2007[Abstract/Free Full Text]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Second-Line Therapy in Gemcitabine-Pretreated Patients With Advanced Pancreatic Cancer
  Stefan Boeck and Volker Heinemann
  JCO 2008 26: 1178-1179 [Full Text]

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kulke, M. H. Articles by Fuchs, C. S. Search for Related Content PubMed Articles by Kulke, M. H. Articles by Fuchs, C. S. Related Articles Related Correspondence Social Bookmarking                            What's this?